China imposes remedies on below-threshold deal for first time

Simcere Pharmaceutical Group has won conditional approval for its acquisition of Beijing Tobishi Pharmaceutical, marking the first time China’s competition authority has remedied a deal that fell below merger notification thresholds.

Unlock unlimited access to all Global Competition Review content